Article

Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: Systematic review

Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand.
BMJ Clinical Research (Impact Factor: 14.09). 05/2001; 322(7297):1271-4. DOI: 10.1136/bmj.322.7297.1271
Source: PubMed

ABSTRACT To assess the effects of oral mucolytics in adults with stable chronic bronchitis and chronic obstructive pulmonary disease.
Systematic review of randomised controlled trials that compared at least two months of regular oral mucolytic drugs with placebo.
Twenty three randomised controlled trials in outpatients in Europe and United States.
Exacerbations, days of illness, lung function, adverse events.
Compared with placebo, the number of exacerbations was significantly reduced in subjects taking oral mucolytics (weighted mean difference -0.07 per month, 95% confidence interval -0.08 to -0.05, P<0.0001). Based on the annualised rate of exacerbations in the control subjects of 2.7 a year, this is a 29% reduction. The number needed to treat for one subject to have no exacerbation in the study period would be 6. Days of illness also fell (weighted mean difference -0.56, -0.77 to -0.35, P<0.0001). The number of subjects who had no exacerbations in the study period was greater in the mucolytic group (odds ratio 2.22, 95% confidence interval 1.93 to 2.54, P<0.0001). There was no difference in lung function or in adverse events reported between treatments.
In chronic bronchitis and chronic obstructive pulmonary disease, treatment with mucolytics is associated with a reduction in acute exacerbations and days of illness. As these drugs have to be taken long term, they could be most useful in patients who have repeated, prolonged, or severe exacerbations of chronic obstructive pulmonary disease.

0 Followers
 · 
137 Views
  • Source
    • "These biochemical changes were accompanied by an improvement in the pulmonary function tests of these patients (Behr et al., 1997). In placebocontrolled trials, orally administered NAC (≥600 mg/day) has been shown to significantly improve the response to steroids, increase the general well-being, and decrease exacerbation rates, emergency room visits, days of illness, costs of hospitalization , and work time loss in patients with chronic lung diseases (Grandjean et al., 2000; Kasielski and Nowak, 2001; Poole and Black, 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute lung injury (ALI) is a life threatening condition associated with hypoxemia, diffuse alveolar damage, inflammation, and loss of lung function. Lipopolysaccharide (LPS; endotoxin) from the outer membrane of Gram-negative bacteria is a major virulence factor involved in the development of ALI. The depletion of glutathione (GSH), an essential intra- and extra-cellular protective antioxidant, by LPS is an important event that contributes to the elevation in reactive oxygen species. Whether restoring GSH homeostasis can effectively ameliorate mitochondrial dysfunction and cellular apoptosis in ALI is unknown and therefore, was the focus of this study. In peripheral lung tissue of LPS-treated mice, hydrogen peroxide and protein nitration levels were significantly increased. Pre-treatment with GSH-ethyl ester (GSH-EE) prevented this increase in oxidative stress. LPS also increased the lactate/pyruvate ratio, attenuated SOD2 protein levels, and decreased ATP levels in the mouse lung indicative of mitochondrial dysfunction. Again, GSH-EE treatment preserved the mitochondrial function. Finally, our studies showed that LPS induced an increase in the mitochondrial translocation of Bax, caspase 3 activation, and nuclear DNA fragmentation and these parameters were all prevented with GSH-EE. Thus, this study suggests that GSH-EE supplementation may reduce the mitochondrial dysfunction associated with ALI.
    Frontiers in Physiology 05/2012; 3:161. DOI:10.3389/fphys.2012.00161 · 3.50 Impact Factor
  • Source
    • "No difference in lung function. Significant reduction in days of disability (0.65 day per patient per month) and 29% reduction in exacerbations (Poole and Black 2001 and 2003) "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic obstructive pulmonary disease (COPD) is associated with a high incidence of morbidity and mortality. Cigarette smoke-induced oxidative stress is intimately associated with the progression and exacerbation of COPD and therefore targeting oxidative stress with antioxidants or boosting the endogenous levels of antioxidants is likely to have beneficial outcome in the treatment of COPD. Among the various antioxidants tried so far, thiol antioxidants and mucolytic agents, such as glutathione, N-acetyl-L-cysteine, N-acystelyn, erdosteine, fudosteine and carbocysteine; Nrf2 activators; and dietary polyphenols (curcumin, resveratrol, and green tea catechins/quercetin) have been reported to increase intracellular thiol status along with induction of GSH biosynthesis. Such an elevation in the thiol status in turn leads to detoxification of free radicals and oxidants as well as inhibition of ongoing inflammatory responses. In addition, specific spin traps, such as alpha-phenyl-N-tert-butyl nitrone, a catalytic antioxidant (ECSOD mimetic), porphyrins (AEOL 10150 and AEOL 10113), and a SOD mimetic M40419 have also been reported to inhibit cigarette smoke-induced inflammatory responses in vivo in the lung. Since a variety of oxidants, free radicals and aldehydes are implicated in the pathogenesis of COPD, it is possible that therapeutic administration of multiple antioxidants and mucolytics will be effective in management of COPD. However, a successful outcome will critically depend upon the choice of antioxidant therapy for a particular clinical phenotype of COPD, whose pathophysiology should be first properly understood. This article will review the various approaches adopted to enhance lung antioxidant levels, antioxidant therapeutic advances and recent past clinical trials of antioxidant compounds in COPD.
    Therapeutic Advances in Respiratory Disease 01/2009; 2(6):351-74. DOI:10.1177/1753465808098224 · 1.95 Impact Factor
  • Source
    • "Mucolytic treatment was associated with a significant reduction of 0.79 exacerbations per patient per year compared to placebo, a 29% decrease (Table 3) (Grandjean et al, 2000; Dekhuijzen, 2004; Decramer et al., 2001; Decramer et al., 2005; Poole and Black, 2003). Although, how mucolytic agents work is still unknown, they may reduce exacerbations by altering mucus production, by breakdown of sulphydryl group, or through antibacterial or immunostimulatory effects (Poole and Black, 2001 and 2003). Pharmacological administration of NAC has been used in an attempt to enhance lung GSH in patients with COPD with varying success (Bridgemen et al., 1994; Rasmusse and Glennow 1988). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glutathione (gamma-glutamyl-cysteinyl-glycine, GSH) is the most abundant intracellular antioxidant thiol and is central to redox defense during oxidative stress. GSH metabolism is tightly regulated and has been implicated in redox signaling and also in protection against environmental oxidant-mediated injury. Changes in the ratio of the reduced and disulfide form (GSH/GSSG) can affect signaling pathways that participate in a broad array of physiological responses from cell proliferation, autophagy and apoptosis to gene expression that involve H(2)O(2) as a second messenger. Oxidative stress due to oxidant/antioxidant imbalance and also due to environmental oxidants is an important component during inflammation and respiratory diseases such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and asthma. It is known to activate multiple stress kinase pathways and redox-sensitive transcription factors such as Nrf2, NF-kappaB and AP-1, which differentially regulate the genes for pro-inflammatory cytokines as well as the protective antioxidant genes. Understanding the regulatory mechanisms for the induction of antioxidants, such as GSH, versus pro-inflammatory mediators at sites of oxidant-directed injuries may allow for the development of novel therapies which will allow pharmacological manipulation of GSH synthesis during inflammation and oxidative injury. This article features the current knowledge about the role of GSH in redox signaling, GSH biosynthesis and particularly the regulation of transcription factor Nrf2 by GSH and downstream signaling during oxidative stress and inflammation in various pulmonary diseases. We also discussed the current therapeutic clinical trials using GSH and other thiol compounds, such as N-acetyl-l-cysteine, fudosteine, carbocysteine, erdosteine in environment-induced airways disease.
    Molecular Aspects of Medicine 09/2008; 30(1-2):60-76. DOI:10.1016/j.mam.2008.07.001 · 10.30 Impact Factor
Show more

Preview

Download
3 Downloads
Available from